Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 1
2009 2
2010 5
2011 4
2012 1
2013 1
2014 3
2015 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.
Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group. Jespersen CM, et al. BMJ. 2006 Jan 7;332(7532):22-7. doi: 10.1136/bmj.38666.653600.55. Epub 2005 Dec 8. BMJ. 2006. PMID: 16339220 Free PMC article. Clinical Trial.
Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.
Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjøller E, Jensen GB, Skoog M, Lindschou J, Gluud C; CLARICOR trial group. Winkel P, et al. Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020. Epub 2015 Jan 6. Int J Cardiol. 2015. PMID: 25602299 Clinical Trial.
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.
Hilden J, Lind I, Kolmos HJ, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Jensen GB, Kastrup J, Kjøller E, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Hilden J, et al. Diagn Microbiol Infect Dis. 2010 Apr;66(4):385-92. doi: 10.1016/j.diagmicrobio.2009.11.011. Diagn Microbiol Infect Dis. 2010. PMID: 20226329 Clinical Trial.
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group. Harutyunyan MJ, et al. Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25. Scand J Clin Lab Invest. 2011. PMID: 21108561 Clinical Trial.
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.
Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM; CLARICOR Trial Group. Gluud C, et al. Cardiology. 2008;111(4):280-7. doi: 10.1159/000128994. Epub 2008 May 2. Cardiology. 2008. PMID: 18451646 Free PMC article. Clinical Trial.
Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group. Lyngbæk S, et al. Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30. Eur J Prev Cardiol. 2014. PMID: 23723326 Clinical Trial.
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Iversen KK, Teisner B, Winkel P, Gluud C, Kjøller E, Kolmos HJ, Hildebrandt PR, Hilden J, Kastrup J; CLARICOR Trial Group. Iversen KK, et al. Atherosclerosis. 2011 Jan;214(1):203-8. doi: 10.1016/j.atherosclerosis.2010.10.025. Epub 2010 Nov 3. Atherosclerosis. 2011. PMID: 21093861 Clinical Trial.
15 results